

Supplementary Material

Synthesis and Study of Prototropic Tautomerism of 2-(2-Furyl)-1-hydroxyimidazoles

Polina A. Nikitina,^{A,B,C} Tatiana Yu. Koldaeva,^A Marina A. Zakharko,^B and Valery P. Perevalov^A

^ADepartment of Fine Organic Synthesis and Chemistry of Dyes, D. I. Mendeleev University of Chemical Technology of Russia, Miusskaya Square, 9, Moscow, 125047, Russia.


^BA. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilova Street, 28, Moscow, 119991, Russia.

^CCorresponding author. Email: polinandrevna@yandex.ru


- 1. Copies of ^1H and ^{13}C NMR spectra of compounds under consideration**
- 2. Copies of 2D NMR spectra of compounds 1a, 2a, 3a.**
- 3. Copies of IR spectra of compounds under consideration**
- 4. Copies of HRMS spectra of compounds under consideration**

1. Copies of ^1H and ^{13}C NMR spectra of compounds under consideration


*1-(2-(Furan-2-yl)-1-hydroxy-4-methyl-1*H*-imidazol-5-yl)ethanone (1a)*




¹H NMR spectrum in CDCl₃:




¹H NMR spectrum in DMSO-d₆:




¹³C NMR spectrum in DMSO-d₆:




¹H NMR spectrum in CD₃OD:




¹³C NMR spectrum in CD₃OD:




*Ethyl 2-(furan-2-yl)-1-hydroxy-4-methyl-1*H*-imidazole-5-carboxylate (**1b**)*




^1H NMR spectrum in CDCl_3 :




¹H NMR spectrum in DMSO-d₆:




¹³C NMR spectrum in DMSO-d₆:




¹H NMR spectrum in CD₃OD:




¹³C NMR spectrum in CD₃OD:




*1-(2-(Furan-2-yl)-1-methoxy-4-methyl-1*H*-imidazol-5-yl)ethanone (2a)*




¹H NMR (CDCl₃):




¹H NMR (DMSO-d₆):




¹³C NMR (DMSO-d₆):




¹H NMR spectrum in CD₃OD:




¹³C NMR spectrum in CD₃OD:




*Ethyl 2-(furan-2-yl)-1-methoxy-4-methyl-1*H*-imidazole-5-carboxylate (**2b**)*




¹H NMR (CDCl₃):




¹H NMR (DMSO-d₆):




¹³C NMR (DMSO-d₆):




¹H NMR spectrum in CD₃OD:




*4-Acetyl-2-(furan-2-yl)-1,5-dimethyl-1*H*-imidazole 3-oxide (3a).*




¹H NMR (CDCl₃):




¹H NMR (DMSO-d₆):




¹³C NMR (DMSO-d₆):




¹H NMR spectrum in CD₃OD:




¹³C NMR spectrum in CD₃OD:




*4-(Ethoxycarbonyl)-2-(furan-2-yl)-1,5-dimethyl-1*H*-imidazole 3-oxide (**3b**).*




¹H NMR (CDCl₃):




¹H NMR (DMSO-d₆):




¹³C NMR (DMSO-d₆):




¹H NMR spectrum in CD₃OD:



Furan-2-yl-N-methylmethanimine (6)




^1H NMR (CDCl_3):




2. Copies of 2D NMR spectra of compounds 1a, 2a, 3a.


1-(2-(Furan-2-yl)-1-hydroxy-4-methyl-1H-imidazol-5-yl)ethanone (1a)




2D HSQC NMR in DMSO-d₆




2D HMBC NMR in DMSO-d₆




1-(2-(Furan-2-yl)-1-methoxy-4-methyl-1*H*-imidazol-5-yl)ethanone (2a**)**




2D HSQC NMR in DMSO-d₆




2D HMBC NMR in DMSO-d₆




*4-Acetyl-2-(furan-2-yl)-1,5-dimethyl-1*H*-imidazole 3-oxide (3a).*



2D HSQC NMR in DMSO-d₆




2D HMBC NMR in DMSO-d₆




3. Copies of IR spectra of compounds under consideration



*1-(2-(Furan-2-yl)-1-hydroxy-4-methyl-1*H*-imidazol-5-yl)ethanone (**1a**)*




IR spectrum of **1a** in KBr:




*Ethyl 2-(furan-2-yl)-1-hydroxy-4-methyl-1*H*-imidazole-5-carboxylate (**1b**)*




*1-(2-(Furan-2-yl)-1-methoxy-4-methyl-1*H*-imidazol-5-yl)ethanone (2a)*




*Ethyl 2-(furan-2-yl)-1-methoxy-4-methyl-1*H*-imidazole-5-carboxylate (2b)*



*4-Acetyl-2-(furan-2-yl)-1,5-dimethyl-1*H*-imidazole 3-oxide (3a).*




*4-(Ethoxycarbonyl)-2-(furan-2-yl)-1,5-dimethyl-1*H*-imidazole 3-oxide (3b).*



4. Copies of HRMS spectra of compounds under consideration

*1-(2-(Furan-2-yl)-1-hydroxy-4-methyl-1*H*-imidazol-5-yl)ethanone (1a)*



Display Report

Analysis Info


Analysis Name D:\Data\Kolotyrkina\2020\Mytianov\0122007.d
Method tune_50-1600.m
Sample Name /MBCI PN-322
Comment C10H10N2O3 mH 207.0764 calibrant added CH3CN

Acquisition Date 22.01.2020 13:24:57


Operator BDAL@DE
Instrument / Ser# micrOTOF 10248

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.0 Bar
Focus	Not active			Set Dry Heater	200 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	1600 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



*Ethyl 2-(furan-2-yl)-1-hydroxy-4-methyl-1*H*-imidazole-5-carboxylate (**1b**)*



Display Report

Analysis Info


Analysis Name D:\Data\Kolotyrkina\2020\Mityanov\0122015.d
Method tune_50-1600.m
Sample Name /MBCI PN-323_R
Comment C11H12N2O4 mH 237.0870 calibrant added CH3CN

Acquisition Date 22.01.2020 15:00:21


Operator BDAL@DE
Instrument / Ser# micrOTOF 10248

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.0 Bar
Focus	Not active			Set Dry Heater	200 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	1600 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



1-(2-(Furan-2-yl)-1-methoxy-4-methyl-1H-imidazol-5-yl)ethanone (2a)



Display Report

Analysis Info


Analysis Name D:\Data\Kolotyrkina\2020\Mityanov\0122012.d
Method tune_50-1600.m
Sample Name /MBCI PN-329
Comment C11H12N2O3 mH 221.0920 calibrant added CH3CN

Acquisition Date 22.01.2020 13:52:00


Operator BDAL@DE
Instrument / Ser# micrOTOF 10248

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.0 Bar
Focus	Not active			Set Dry Heater	200 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	1600 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



Ethyl 2-(furan-2-yl)-1-methoxy-4-methyl-1H-imidazole-5-carboxylate (2b)




Display Report

Analysis Info


Analysis Name D:\Data\Kolotyrkina\2020\Mityanov\0122013.d Acquisition Date 22.01.2020 13:58:17
Method tune_50-1600.m Operator BDAL@DE
Sample Name /MBCI PN-334 Instrument / Ser# micrOTOF 10248
Comment C12H14N2O4 mh 251.1026 calibrant added CH3CN

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.0 Bar
Focus	Not active			Set Dry Heater	200 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	1600 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



4-Acetyl-2-(furan-2-yl)-1,5-dimethyl-1H-imidazole 3-oxide (3a**).**



Display Report

Analysis Info


Analysis Name D:\Data\Kolotyrkina\2020\Mityanov\0122011.d
 Method tune_50-1600.m
 Sample Name /MBCI PN-328
 Comment C11H12N2O3 mH 221.0920 calibrant added CH3CN

Acquisition Date 22.01.2020 13:47:19


Operator BDAL@DE
 Instrument / Ser# micrOTOF 10248

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.0 Bar
Focus	Not active			Set Dry Heater	200 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	1600 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste



4-(Ethoxycarbonyl)-2-(furan-2-yl)-1,5-dimethyl-1H-imidazole 3-oxide (3b**).**



Display Report

Analysis Info

Analysis Name D:\Data\Kolotyrkina\2020\Mityanov\0122014.d
 Method tune_50-1600.m
 Sample Name /MBCI PN-357
 Comment C12H14N2O4 mH 251.1026 calibrant added CH3CN

Acquisition Date 22.01.2020 14:02:16

Operator BDAL@DE
 Instrument / Ser# micrOTOF 10248

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	1.0 Bar
Focus	Not active			Set Dry Heater	200 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	1600 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste

